CytoMed Therapeutics (NASDAQ:GDTC) Posts Quarterly Earnings Results

CytoMed Therapeutics (NASDAQ:GDTC) announced its quarterly earnings data on Tuesday. The company reported ($0.06) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.06 million during the quarter.

CytoMed Therapeutics Trading Up 3.0%

Shares of NASDAQ GDTC opened at $1.03 on Thursday. The firm’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.54. CytoMed Therapeutics has a 52-week low of $0.73 and a 52-week high of $3.68.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of CytoMed Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.